Osteopontin expression in ovarian carcinomas and tumors of low malignant potential (LMP)

Human Pathology

Volumn 29, Issue 11, 1998, Pages 1250-1254

  Tiniakos, Dina G ^a   Yu, Helen ^a   Liapis, Helen ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BARNES JEWISH HOSPITAL   (United States)

Author keywords

Borderline tumors; Osteopontin; Ovarian cancer

Indexed keywords

OSTEOPONTIN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LYMPH NODE METASTASIS; METASTASIS; OVARY CARCINOMA; PROGNOSIS; PROTEIN EXPRESSION;

EID: 0031760836     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(98)90253-2     Document Type: Article

References (16)

1. International Federation of Gynaecology and Obstetrics: Classification and staging of malignant tumors in the female pelvis. Acta Obstet Gynaecol Scand 50:1-7, 1971
2. Serov SF, Scully RE, Sobin LH: International histological classification of tumors No. 9: Histological typing of ovarian tumors. Geneva, Switzerland, World Health Organization, 1973
3. Tazelaar HD, Bostwick DG, Ballon SC, et al: Conservative treatment of borderline ovarian tumors. Obstet Gynecol 66:417-422, 1985
4. Basil JB, Kost ER, Liapis H, et al: Recurrent ovarian low malignant potential tumor with cardiac metastasis. Obstet Gynecol 89:854-856, 1997
5. 3 integrin is less frequent in ovarian epithelial tumors of low malignant potential in contrast to ovarian carcinomas. HUM PATHOL 28:443-449, 1997
6. 3 potentiate bone resorption. J Biol Chem 268:9901-9907, 1993
7. Brown LF, Berse B, Van De Water L, et al: Expression and distribution of osteopontin in human tissues: Widespread association with luminal epithelial surfaces. Mol Biol Cell 3:1169-1180, 1992
8. Bellahcène A, Castronovo V: Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Am J Pathol 146:95-100, 1995
9. Brown LF, Papadopoulos-Sergiou A, Berse B, et al: Osteopontin expression and distribution in human carcinomas. Am J Pathol 145:610-623, 1994
10. Denhardt DT, Guo X: Osteopontin: A protein with diverse functions. FASEBJ 7:1475-1482, 1993
11. American Joint Committee on Cancer: Manual for staging of cancer (ed 5). Philadelphia, PA, Lippincott, 1997
12. Fisher LW, Lindner W, Young MF, et al: Synthetic peptide antisera: Their production and use in the cloning of matrix proteins. Connect Tissue Res 21:43-50, 1989 (abstr)
13. Liapis H, Crouch EC, Grosso LE, et al: Expression of parathyroidlike protein in normal, proliferative, and neoplastic human breast tissues. Am J Pathol 143:1169-1178, 1993
14. Giachelli CM, Bae N, Almeie M, et al: Osteopontin is elevated during neointimal formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest 92:1686-1696, 1993
15. Hwang S-M, Wilson PD, Laskin JD, et al: Age and development-related changes in osteopontin and nitric oxide synthase mRNA levels in human kidney proximal tubule epithelial cells: Contrasting responses to hypoxia and reoxygenation. J Cell Physiology 160:61-68, 1994
16. Senger DR, Peruzzi CA, Papadopoulos A: Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation. Anticancer Res 9:1291-1300, 1989